GALECTIN THERAPEUTICS INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
GALECTIN THERAPEUTICS INC. (GALT) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $0 for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-30.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2023-03-30
- GALECTIN THERAPEUTICS INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- GALECTIN THERAPEUTICS INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2021 was $532.45K, a 1238.08% increase from fiscal 2020.
- GALECTIN THERAPEUTICS INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2020 was $39.79K, a 93.30% decline from fiscal 2019.
- GALECTIN THERAPEUTICS INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2019 was $594.30K, a 94.63% decline from fiscal 2018.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 150 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 162 month |
|---|---|---|---|
| 2022-12-31 | $0.00 10-K · filed 2023-03-30 | ||
| 2021-12-31 | $532.45K 10-K · filed 2023-03-30 | ||
| 2020-12-31 | $39.79K 10-K · filed 2022-03-31 | ||
| 2019-12-31 | $594.30K 10-K · filed 2021-03-31 | ||
| 2018-12-31 | $11.08M 10-K · filed 2020-03-16 | ||
| 2013-12-31 | $1.50M 10-K · filed 2014-03-21 | $3.22M 10-K · filed 2014-03-21 | |
| 2012-12-31 | $162.00K 10-K · filed 2014-03-21 | $1.72M 10-K · filed 2013-03-29 | |
| 2011-12-31 | $1.17M 10-K · filed 2013-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |